Optometrists in Goffstown, NH Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Norman G. Michaud, Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 89 S Mast St, Goffstown, NH 03045 Phone: 603-497-3622 Fax: 603-497-5325 |
 Dr. Norman G Michaud, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 24 Main Street, Goffstown, NH 03045 Phone: 603-497-3622 Fax: 603-497-5325 |
Dr. Jeffrey P Michaud, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 24 Main Street, Goffstown, NH 03045 Phone: 603-497-3622 Fax: 603-497-5325 |
News Archive
TAVR shows high rate of success and low risk of death in patients with bicuspid valve
Transcatheter aortic valve replacement procedures had a high rate of success and low risk of death or disabling stroke at 30 days in patients with a bicuspid, or two-leaflet, aortic valve, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Older women destined to develop AD have high blood levels of pregnancy protein
In an advance toward a much-needed early diagnostic test for Alzheimer's disease (AD), scientists have discovered that older women destined to develop AD have high blood levels of a protein linked to pregnancy years before showing symptoms.
Austin Recovery, Emmy Award-winning 'Intervention' program team up to save an addict's life
Austin Recovery, the largest and most affordable not-for-profit drug and alcohol treatment center in Texas, has once again teamed up with the Emmy Award-winning "Intervention" program to save an addict's life.
Medically active component of cannabis does not impact driving ability, study shows
A landmark study on how cannabis affects driving ability has shown that cannabidiol (CBD), a cannabis component now widely used for medical purposes, does not impair driving, while moderate amounts of the main intoxicating component tetrahydrocannabinol (THC) produce mild driving impairment lasting up to four hours.
Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
› Verified 2 days ago
Physical Therapists
Chiropractors
Occupational Therapists
Speech-Language Pathologists
Optometrists